IL6 and COVID-19: As might be expected, the plasma concentrations of prototypical inflammatory mediators TNFα, IL-1β, and IL-6 have been frequently reported in COVID-19 studies and seem to increase relative to infection severity in most patients.25,31 The concentrations of other ligands with known receptors in the hDRG have been less commonly reported.